A medication commonly used for autoimmune diseases like rheumatoid arthritis has proven effective for patients with giant cell arteritis, according to a Phase 3 clinical trial led by researchers at the Perelman School of Medicine, University of Pennsylvania. Published in the New England Journal of Medicine, the study found that Upadacitinib helped nearly half of patients achieve sustained remission while reducing reliance on glucocorticoids, which often cause severe side effects.
Giant cell arteritis is an autoimmune disorder where the immune system attacks blood vessels in the head, neck, and other areas, leading to headaches, vision loss, and even aortic aneurysms. The current standard treatment involves glucocorticoids like prednisone, but these drugs can cause weight gain, diabetes, and other serious complications.
The trial involved 100 sites across 24 countries, with patients randomized into three groups: one receiving a placebo, and two receiving different doses of Upadacitinib (7.5 mg or 15 mg daily). By the study’s end, 46% of patients taking the higher dose achieved sustained remission-a significant improvement compared to 29% in the placebo group. The lower dose also showed promise, though its results were not statistically significant.
Dr. Peter A. Merkel, the study’s senior author, emphasized the potential impact: “This could help patients stop taking glucocorticoids, control their disease, and improve their quality of life.”
The findings highlight Upadacitinib as a viable alternative for managing giant cell arteritis, offering hope for reduced dependency on glucocorticoids. Future research may explore its long-term benefits and broader applications for inflammatory diseases. The study underscores the importance of targeting the JAK-STAT pathway, a key player in immune system inflammation.
Add comment